|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 317.23 USD | -1.00% |
|
-1.02% | -20.22% |
| 06/03 | Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement | CI |
| 05/03 | Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments | RE |
Company Valuation: Alnylam Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 20,282 | 29,238 | 24,021 | 30,350 | 52,535 | 42,496 | - | - |
| Change | - | 44.16% | -17.84% | 26.35% | 73.09% | -19.11% | - | - |
| Enterprise Value (EV) 1 | 18,522 | 28,132 | 23,979 | 30,128 | 52,535 | 39,102 | 35,885 | 33,607 |
| Change | - | 51.88% | -14.76% | 25.64% | 74.37% | -25.57% | -8.23% | -6.35% |
| P/E ratio | -23.6x | -25.6x | -54.4x | -108x | 171x | 47.8x | 29.5x | 23.2x |
| PBR | 34.6x | -186x | -109x | 453x | - | 19x | 9.61x | 5.84x |
| PEG | - | -0.9x | 0.9x | 2.8x | -1x | 0x | 0.5x | 0.8x |
| Capitalization / Revenue | 24x | 28.2x | 13.1x | 13.5x | 14.1x | 7.61x | 5.84x | 4.9x |
| EV / Revenue | 21.9x | 27.1x | 13.1x | 13.4x | 14.1x | 7.01x | 4.93x | 3.88x |
| EV / EBITDA | -28x | -38x | -105x | -251x | - | 33.5x | 19.8x | 13.3x |
| EV / EBIT | -26.1x | -35.8x | -85x | -170x | 105x | 34.8x | 19.3x | 14.4x |
| EV / FCF | -25.8x | -45.9x | 572x | -707x | - | 29.1x | 18.2x | 14x |
| FCF Yield | -3.88% | -2.18% | 0.17% | -0.14% | - | 3.44% | 5.49% | 7.16% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.2 | -9.3 | -3.52 | -2.18 | 2.33 | 6.706 | 10.86 | 13.84 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 844.3 | 1,037 | 1,828 | 2,248 | 3,714 | 5,581 | 7,282 | 8,670 |
| EBITDA 1 | -661.1 | -740.6 | -228.1 | -120.2 | - | 1,166 | 1,811 | 2,522 |
| EBIT 1 | -708.7 | -785.1 | -282.2 | -176.9 | 501.6 | 1,123 | 1,857 | 2,339 |
| Net income 1 | -852.8 | -1,131 | -440.2 | -278.2 | 313.7 | 942.6 | 1,523 | 1,969 |
| Net Debt 1 | -1,760 | -1,105 | -41.37 | -222.5 | - | -3,394 | -6,611 | -8,890 |
| Reference price 2 | 169.58 | 237.65 | 191.41 | 235.31 | 397.65 | 320.43 | 320.43 | 320.43 |
| Nbr of stocks (in thousands) | 1,19,601 | 1,23,028 | 1,25,493 | 1,28,981 | 1,32,114 | 1,32,623 | - | - |
| Announcement Date | 10/02/22 | 23/02/23 | 15/02/24 | 13/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 47.78x | 7.01x | 33.54x | -.--% | 4.25TCr | |
| 29.39x | 11.07x | 22.23x | 0.66% | 89TCr | |
| 25.78x | 6x | 16.34x | 2.18% | 59TCr | |
| 24.73x | 6.77x | 13.58x | 3.04% | 40TCr | |
| 17.77x | 4.33x | 10.71x | 3.05% | 34TCr | |
| 24.42x | 5.09x | 14.09x | 1.71% | 30TCr | |
| 21.17x | 5.7x | 14.1x | 2.84% | 30TCr | |
| 27.16x | 4.76x | 14.89x | 2.9% | 29TCr | |
| 25.41x | 6.42x | 11.43x | 2.66% | 20TCr | |
| 20.24x | 6.16x | 11.14x | 2.23% | 18TCr | |
| Average | 26.38x | 6.33x | 16.20x | 2.13% | 35.32TCr | |
| Weighted average by Cap. | 25.37x | 7.05x | 16.13x | 2.06% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ALNY Stock
- Valuation Alnylam Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition